GLP-1 Agonist Therapy Center

The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c. 

Infusion of certain hormones could help in reducing patient weight and glucose levels. 

A promising new study paves the way for a new pharmacologic treatment to regenerate beta cells in patients with diabetes. 

A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.

Analysis of the PIONEER 8 trial reveals dose-dependent reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens.

A new study compares GLP-1 receptor agonists with known cardiovascular benefits against each other, rather than against the traditional placebo. 

Danish study makes strong recommendations for diabetes pharmacotherapy beyond metformin. 

We were following up with a person with type 2 diabetes who was recently started on the new oral formulation of the GLP-1 receptor agonists semaglutide (Rybelsus®). This patient had a 12-year history of type 2 diabetes as well as several comorbidities that included hypertension, hyperlipidemia, obesity (BMI = 33 kg/m2), knee osteoarthritis, and hypothyroidism. The patient was previously resistant to initiating a GLP-1 receptor agonist due to his hesitancy toward self-injection. He agreed at his last primary care visit to start a trial of oral semaglutide to improve his glucose control and lose some weight....

The MAG1C interventional study was a single-center, 26-week, phase 2a, to look at how Exenatide might benefit patients with type 1 diabetes. 

Eliminating childhood obesity, one injection at a time.